Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis

References

• Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull. 2009;35(3):528–548.
   PubMed Web of Science ®Google Scholar
• Larson MK, Walker EF, Compton MT. Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. Expert Rev Neurother. 2010;10(8):1347–1359.
   PubMed Web of Science ®Google Scholar
• Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151(10):1409–1416.
   PubMed Web of Science ®Google Scholar
• Harrow M, Jobe T, Faull R. Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. Psychol Med. 2014;44(14):3007–3016.
   PubMed Web of Science ®Google Scholar
• Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res. 2014;152(2–3):408–414.
   PubMed Web of Science ®Google Scholar
• Eack SM, Newhill CE. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull. 2007;33(5):1225–1237.
   PubMed Web of Science ®Google Scholar
• Kennedy JL, Altar CA, Taylor DL, et al. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29(2):63–76.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;2005(353):1209–1223.
   Google Scholar
• Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.
   PubMed Web of Science ®Google Scholar
• Lally J, Ajnakina O, Di Forti M, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med. 2016;46(15):3231–3240.
   PubMed Web of Science ®Google Scholar
• Kapur S, Remington G. Dopamine D 2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry. 2001;50(11):873–883.
   PubMed Web of Science ®Google Scholar
• Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophr Bull. 2009;35(3):549–562.
   PubMed Web of Science ®Google Scholar
• Demjaha A, Lappin J, Stahl D, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;1–9.
   Web of Science ®Google Scholar
• Demjaha A, Egerton A, Murray RM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014;75(5):e11–e3.
   PubMed Web of Science ®Google Scholar
• Chouinard G, Samaha A-N, Chouinard V-A, et al. Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy. Psychother Psychosom. 2017;86(4):189–219.
   PubMed Web of Science ®Google Scholar
• Benes FM, Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology. 2001;25(1):1–27.
   PubMed Web of Science ®Google Scholar
• McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020;19(1):15–33.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223.
   PubMed Web of Science ®Google Scholar
• Marek G. When is a proof-of-concept (POC) not a POC? Pomaglumetad (LY2140023) as a case study for antipsychotic efficacy. Curr Pharm Des. 2015;21(26):3788–3796.
   PubMed Web of Science ®Google Scholar
• Bespalov A, Steckler T, Altevogt B, et al. Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets. Nat Rev Drug Discov. 2016;15(7):516.
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi-Dargham A, Van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Nat Acad Sci. 1996;93(17):9235–9240.
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Gil R, Krystal J, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry. 1998;155(6):761–767.
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi-Dargham A, Gil R, et al. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry. 1999;46(1):56–72.
   PubMed Web of Science ®Google Scholar
• Howes OD, Kambeitz J, Kim E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies. Arch Gen Psychiatry. 2012;69(8):776–786.
   PubMed Web of Science ®Google Scholar
• Kegeles LS, Abi-Dargham A, Frankle WG, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry. 2010;67(3):231–239.
   PubMed Web of Science ®Google Scholar
• McCutcheon R, Beck K, Jauhar S, et al. Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis. Schizophr Bull. 2017;44(6):1301–1311.
   Web of Science ®Google Scholar
• Howes OD, Montgomery AJ, Asselin M-C, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66(1):13–20.
   PubMed Web of Science ®Google Scholar
• Howes OD, Bose SK, Turkheimer F, et al. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry. 2011;168(12):1311–1317.
   PubMed Web of Science ®Google Scholar
• Howes O, Bose S, Turkheimer F, et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry. 2011;16(9):885–886.
   PubMed Web of Science ®Google Scholar
• Egerton A, Chaddock CA, Winton-Brown TT, et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol Psychiatry. 2013;74(2):106–112.
   PubMed Web of Science ®Google Scholar
• Slifstein M, van de Giessen E, Van Snellenberg J, et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry. 2015;72(4):316–324.
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Girgis RR, Gray DL, et al. Novel dopamine therapeutics for cognitive deficits in schizophrenia. Biol Psychiatry. 2017;81(1):67–77.
   PubMed Web of Science ®Google Scholar
• Girgis RR, Zoghbi AW, Javitt DC, et al. The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: a critical and comprehensive review. J Psychiatric Res. 2019;108:57–83.
   PubMed Web of Science ®Google Scholar
• Valenti O, Cifelli P, Gill KM, et al. Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia. J Neurosci. 2011;31(34):12330–12338.
   PubMed Web of Science ®Google Scholar
• Grace A, Bunney B. Induction of depolarization block in midbrain dopamine neurons by repeated administration of haloperidol: analysis using in vivo intracellular recording. J Pharmacol Exp Ther. 1986;238(3):1092–1100.
   PubMed Web of Science ®Google Scholar
• Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci. 1983;3(8):1607–1619.
   PubMed Web of Science ®Google Scholar
• Grace AA, Bunney BS, Moore H, et al. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci. 1997;20(1):31–37.
   PubMed Web of Science ®Google Scholar
• Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400.
   PubMed Web of Science ®Google Scholar
• Burris K, Molski T, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381–389.
   PubMed Web of Science ®Google Scholar
• Sonnenschein SF, Gill KM, Grace AA. State-dependent effects of the D 2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia. Neuropsychopharmacology. 2019;44(3):572.
   PubMed Web of Science ®Google Scholar
• Lodge DJ, Grace AA. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol Sci. 2011;32(9):507–513.
   PubMed Web of Science ®Google Scholar
• Poels E, Kegeles L, Kantrowitz J, et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry. 2014;19(1):20–29.
   PubMed Web of Science ®Google Scholar
• Schobel SA, Lewandowski NM, Corcoran CM, et al. Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry. 2009;66(9):938–946.
   PubMed Web of Science ®Google Scholar
• Talati P, Rane S, Kose S, et al. Increased hippocampal CA1 cerebral blood volume in schizophrenia. NeuroImage: Clin. 2014;5:359–364.
   PubMed Web of Science ®Google Scholar
• Medoff DR, Holcomb HH, Lahti AC, et al. Probing the human hippocampus using rCBF: contrasts in schizophrenia. Hippocampus. 2001;11(5):543–550.
   PubMed Web of Science ®Google Scholar
• Malaspina D, Harkavy-Friedman J, Corcoran C, et al. Resting neural activity distinguishes subgroups of schizophrenia patients. Biol Psychiatry. 2004;56(12):931–937.
   PubMed Web of Science ®Google Scholar
• Schobel SA, Chaudhury NH, Khan UA, et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron. 2013;78(1):81–93.
   PubMed Web of Science ®Google Scholar
• McHugo M, Talati P, Armstrong K, et al. Hyperactivity and reduced activation of anterior hippocampus in early psychosis. Am J Psychiatry. 2019;176(12):1030–1038.
   PubMed Web of Science ®Google Scholar
• Provenzano FA, Guo J, Wall MM, et al. Hippocampal pathology in clinical high-risk patients and the onset of schizophrenia. Biol Psychiatry. 2019; 87(3), 234-242.
   PubMed Web of Science ®Google Scholar
• Allen P, Azis M, Modinos G, et al. Increased resting hippocampal and basal ganglia perfusion in people at ultra high risk for psychosis: replication in a second cohort. Schizophr Bull. 2017;44(6):1323–1331.
   Web of Science ®Google Scholar
• Modinos G, Egerton A, McMullen K, et al. Increased resting perfusion of the hippocampus in high positive schizotypy: a pseudocontinuous arterial spin labeling study. Hum Brain Mapp. 2018;39(10):4055–4064.
   PubMed Web of Science ®Google Scholar
• Bossong MG, Antoniades M, Azis M, et al. Association of hippocampal glutamate levels with adverse outcomes in individuals at clinical high risk for psychosis. JAMA Psychiatry. 2019;76(2):199–207.
   PubMed Web of Science ®Google Scholar
• Kraguljac NV, White DM, Hadley J, et al. Hippocampal‐parietal dysconnectivity and glutamate abnormalities in unmedicated patients with schizophrenia. Hippocampus. 2014;24(12):1524–1532.
   PubMed Web of Science ®Google Scholar
• Kraguljac NV, White DM, Reid MA, et al. Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry. 2013;70(12):1294–1302.
   PubMed Web of Science ®Google Scholar
• Howes OD, Bonoldi I, McCutcheon RA, et al. Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study. Neuropsychopharmacology. 2019;45(4):641-648.
   Web of Science ®Google Scholar
• Stone JM, Howes OD, Egerton A, et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol Psychiatry. 2010;68(7):599–602.
   PubMed Web of Science ®Google Scholar
• Merritt K, Egerton A, Kempton MJ, et al. Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies. JAMA Psychiatry. 2016;73(7):665–674.
   PubMed Web of Science ®Google Scholar
• Bustillo J, Rowland L, Mullins P, et al. 1 H-MRS at 4 tesla in minimally treated early schizophrenia. Mol Psychiatry. 2010;15(6):629–636.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Engberg G, Shimizu E, et al. Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry. 2005;5(1):6.
   PubMedGoogle Scholar
• Konradi C, Yang CK, Zimmerman EI, et al. Hippocampal interneurons are abnormal in schizophrenia. Schizophr Res. 2011;131(1):165–173.
   PubMed Web of Science ®Google Scholar
• Heckers S, Konradi C. GABAergic mechanisms of hippocampal hyperactivity in schizophrenia. Schizophr Res. 2015;167(1):4–11.
   PubMed Web of Science ®Google Scholar
• Lodge DJ, Behrens MM, Grace AA. A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J Neurosci. 2009;29(8):2344–2354.
   PubMed Web of Science ®Google Scholar
• Moore H, Jentsch JD, Ghajarnia M, et al. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry. 2006;60(3):253–264.
   PubMed Web of Science ®Google Scholar
• Johnston M, Carman A, Coyle J. Effects of fetal treatment with methylazoxymethanol acetate at various gestational dates on the neurochemistry of the adult neocortex of the rat. J Neurochem. 1981;36(1):124–128.
   PubMed Web of Science ®Google Scholar
• Modinos G, Allen P, Grace AA, et al. Translating the MAM model of psychosis to humans. Trends Neurosci. 2015;38(3):129–138.
   PubMed Web of Science ®Google Scholar
• Flagstad P, Mørk A, Glenthøj BY, et al. Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens. Neuropsychopharmacology. 2004;29(11):2052.
   PubMed Web of Science ®Google Scholar
• Lodge DJ, Grace AA. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci. 2007;27(42):11424–11430.
   PubMed Web of Science ®Google Scholar
• Floresco SB, Todd CL, Grace AA. Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. J Neurosci. 2001;21(13):4915–4922.
   PubMed Web of Science ®Google Scholar
• Lodge DJ, Grace AA. The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation. Neuropsychopharmacology. 2006;31(7):1356.
   PubMed Web of Science ®Google Scholar
• Sonnenschein SF, Gomes FV, Grace AA. Dysregulation of Midbrain Dopamine System and the Pathophysiology of Schizophrenia. Front Psychiatry. 2020;11:613.
   PubMed Web of Science ®Google Scholar
• Gill KM, Cook JM, Poe MM, et al. Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. Schizophr Bull. 2014;40(2):341–350.
   PubMed Web of Science ®Google Scholar
• Perez SM, Lodge DJ. Hippocampal interneuron transplants reverse aberrant dopamine system function and behavior in a rodent model of schizophrenia. Mol Psychiatry. 2013;18(11):1193.
   PubMed Web of Science ®Google Scholar
• Sim F, Sweetman I, Kapur S, et al. Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review. J Psychopharmacol. 2015;29(2):212–223.
   PubMed Web of Science ®Google Scholar
• Stefanits H, Milenkovic I, Mahr N, et al. GABAA receptor subunits in the human amygdala and hippocampus: immunohistochemical distribution of 7 subunits. J Comp Neurol. 2018;526(2):324–348.
   PubMed Web of Science ®Google Scholar
• Glykys J, Mann EO, Mody I. Which GABAA receptor subunits are necessary for tonic inhibition in the hippocampus? J Neurosci. 2008;28(6):1421–1426.
   PubMed Web of Science ®Google Scholar
• Caraiscos VB, Elliott EM, You-Ten KE, et al. Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by α5 subunit-containing γ-aminobutyric acid type A receptors. Proc Nat Acad Sci. 2004;101(10):3662–3667.
   PubMed Web of Science ®Google Scholar
• Bonin RP, Martin LJ, MacDonald JF, et al. α5GABAA receptors regulate the intrinsic excitability of mouse hippocampal pyramidal neurons. J Neurophysiol. 2007;98(4):2244–2254.
   PubMed Web of Science ®Google Scholar
• Gill KM, Lodge DJ, Cook JM, et al. A novel α5GABAAR-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. Neuropsychopharmacology. 2011;36(9):1903.
   PubMed Web of Science ®Google Scholar
• Biggs CS, Pearce BR, Fowler LJ, et al. The effect of sodium valproate on extracellular GABA and other amino acids in the rat ventral hippocampus: an in vivo microdialysis study. Brain Res. 1992;594(1):138–142.
   PubMed Web of Science ®Google Scholar
• Löscher W. Valproate enhances GABA turnover in the substantia nigra. Brain Res. 1989;501(1):198–203.
   PubMed Web of Science ®Google Scholar
• Tremolizzo L, Doueiri M-S, Dong E, et al. Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol Psychiatry. 2005;57(5):500–509.
   PubMed Web of Science ®Google Scholar
• Tremolizzo L, Carboni G, Ruzicka W, et al. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc Nat Acad Sci. 2002;99(26):17095–17100.
   PubMed Web of Science ®Google Scholar
• Basan A, Kissling W, Leucht S. Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Schizophr Res. 2004;70(1):33–37.
   PubMed Web of Science ®Google Scholar
• Tseng P-T, Chen Y-W, Chung W, et al. Significant effect of valproate augmentation therapy in patients with schizophrenia: a meta-analysis study. Medicine. 2016;95:4.
   Web of Science ®Google Scholar
• Wang Y, Xia J, Helfer B, et al. Valproate for schizophrenia. Cochrane Database Syst Rev. 2016;11: 1-136.
   Web of Science ®Google Scholar
• Gomes FV, Zhu X, Grace AA. The pathophysiological impact of stress on the dopamine system is dependent on the state of the critical period of vulnerability. Mol psychiatry. 2019Sep 5:10.1038/s41380-019-0514-1. doi: 10.1038/s41380-019-0514-1. Epub ahead of print. Erratum in: Mol Psychiatry. 2019 Sep 27;: PMID: 31488866; PMCID: PMC7056584..
   PubMedGoogle Scholar
• Silingardi D, Scali M, Belluomini G, et al. Epigenetic treatments of adult rats promote recovery from visual acuity deficits induced by long‐term monocular deprivation. Eur J Neurosci. 2010;31(12):2185–2192.
   PubMed Web of Science ®Google Scholar
• Baroncelli L, Scali M, Sansevero G, et al. Experience affects critical period plasticity in the visual cortex through an epigenetic regulation of histone post-translational modifications. J Neurosci. 2016;36(12):3430–3440.
   PubMed Web of Science ®Google Scholar
• Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007;27(43):11496–11500.
   PubMed Web of Science ®Google Scholar
• Tsai GE, Lin P-Y. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Current Pharmaceutical Design. 2010;16(5):522–537.
   PubMed Web of Science ®Google Scholar
• Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2005;72(2–3):225–234.
   PubMed Web of Science ®Google Scholar
• Javitt DC. Glycine transport inhibitors in the treatment of schizophrenia. Novel Antischizophrenia Treat. 2012;367–399. Springer.
   Google Scholar
• Tsai G, Lane H-Y, Yang P, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2004;55(5):452–456.
   PubMed Web of Science ®Google Scholar
• Lane H-Y, Chang Y-C, Liu Y-C, et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005;62(11):1196–1204.
   PubMed Web of Science ®Google Scholar
• Lane H-Y, Lin C-H, Huang Y-J, et al. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol. 2010;13(4):451–460.
   PubMed Web of Science ®Google Scholar
• Lane H-Y, Liu Y-C, Huang C-L, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry. 2008;63(1):9–12.
   PubMed Web of Science ®Google Scholar
• Bugarski-Kirola D, Wang A, Abi-Saab D, et al. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia–results from the CandleLyte study. Eur Neuropsychopharmacol. 2014;24(7):1024–1036.
   PubMed Web of Science ®Google Scholar
• Lane H-Y, Huang C-L, Wu P-L, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry. 2006;60(6):645–649.
   PubMed Web of Science ®Google Scholar
• Lane H-Y, Lin C-H, Green MF, et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of d-amino acid oxidase inhibitor. JAMA Psychiatry. 2013;70(12):1267–1275.
   PubMed Web of Science ®Google Scholar
• Lin C-H, Lin C-H, Chang Y-C, et al. Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2018;84(6):422–432.
   PubMed Web of Science ®Google Scholar
• Lin C-Y, Liang S-Y, Chang Y-C, et al. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial. World J Biol Psychiatry. 2017;18(5):357–368.
   PubMed Web of Science ®Google Scholar
• Nicoletti F, Bockaert J, Collingridge G, et al. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology. 2011;60(7–8):1017–1041.
   PubMed Web of Science ®Google Scholar
• Lavreysen H, Langlois X, Ahnaou A, et al. Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H] JNJ-40068782. J Pharmacol Exp Ther. 2013;346(3):514–527.
   PubMed Web of Science ®Google Scholar
• Rorick-Kehn LM, Johnson BG, Knitowski KM, et al. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl). 2007;193(1):121–136.
   PubMed Web of Science ®Google Scholar
• Mezler M, Geneste H, Gault L, et al. 2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Invest Drugs. 2010;11(7):833–845.
   PubMedGoogle Scholar
• Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov. 2009;8(1):41.
   PubMed Web of Science ®Google Scholar
• Pehrson AL, Moghaddam B. Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion. Psychopharmacology (Berl). 2010;211(4):443–455.
   PubMed Web of Science ®Google Scholar
• Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998;281(5381):1349–1352.
   PubMed Web of Science ®Google Scholar
• Sonnenschein SF, Grace AA. The mGluR2/3 agonist pomaglumetad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus. Neuropsychopharmacology. 2020 Nov;45(12):2106-2113. doi: 10.1038/s41386-020-0764-2. Epub 2020 Jul 14. PMID: 32663839; PMCID: PMC7547679..
   Google Scholar
• Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13(9):1102–1107.
   PubMed Web of Science ®Google Scholar
• Adams DH, Kinon BJ, Baygani S, et al. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC Psychiatry. 2013;13(1):143.
   PubMedGoogle Scholar
• Stauffer VL, Millen BA, Andersen S, et al. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res. 2013;150(2–3):434–441.
   PubMed Web of Science ®Google Scholar
• Downing AM, Kinon BJ, Millen BA, et al. A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry. 2014;14(1):351.
   PubMedGoogle Scholar
• Adams DH, Zhang L, Millen BA, et al. Pomaglumetad methionil (LY2140023 monohydrate) and aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison. Schizophr Res Treat. 2014;2014.
   Google Scholar
• Kinon BJ, Millen BA, Zhang L, et al. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol Psychiatry. 2015;78(11):754–762.
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Grinband J, Goff DC, et al. Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: rCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers. Neuropsychopharmacology. 2020;45(11):1842-1850.
   Web of Science ®Google Scholar
• Howes O, McCutcheon R. Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. Transl Psychiatry. 2017;7(2):e1024–e.
   PubMedGoogle Scholar
• Grace AA. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nat Rev Neurosci. 2016;17(8):524.
   PubMed Web of Science ®Google Scholar
• Do KQ, Cuenod M, Hensch TK. Targeting oxidative stress and aberrant critical period plasticity in the developmental trajectory to schizophrenia. Schizophr Bull. 2015;41(4):835–846.
   PubMed Web of Science ®Google Scholar
• Cai Z, Pan Z-L, Pang Y, et al. Cytokine induction in fetal rat brains and brain injury in neonatal rats after maternal lipopolysaccharide administration. Pediatr Res. 2000;47(1):64.
   PubMed Web of Science ®Google Scholar
• Urakubo A, Jarskog LF, Lieberman JA, et al. Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain. Schizophr Res. 2001;47(1):27–36.
   PubMed Web of Science ®Google Scholar
• Gilmore JH, Jarskog LF, Vadlamudi S. Maternal poly I: C exposure during pregnancy regulates TNFα, BDNF, and NGF expression in neonatal brain and the maternal–fetal unit of the rat. J Neuroimmunol. 2005;159(1–2):106–112.
   PubMed Web of Science ®Google Scholar
• Ashdown H, Dumont Y, Ng M, et al. The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia. Mol Psychiatry. 2006;11(1):47–55.
   PubMed Web of Science ®Google Scholar
• Smith SE, Li J, Garbett K, et al. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci. 2007;27(40):10695–10702.
   PubMed Web of Science ®Google Scholar
• Giovanoli S, Engler H, Engler A, et al. Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science. 2013;339(6123):1095–1099.
   PubMed Web of Science ®Google Scholar
• Müller N, Myint A-M, Krause D, et al. Anti-inflammatory treatment in schizophrenia. Progress Neuro-Psychopharmacol Biol Psychiatry. 2013;42:146–153.
   PubMed Web of Science ®Google Scholar
• Tomasik J, Rahmoune H, Guest PC, et al. Neuroimmune biomarkers in schizophrenia. Schizophr Res. 2016;176(1):3–13.
   PubMed Web of Science ®Google Scholar
• Chan MK, Krebs M, Cox D, et al. Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset. Transl Psychiatry. 2015;5(7):e601–e.
   PubMedGoogle Scholar
• Perkins DO, Jeffries CD, Addington J, et al. Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project. Schizophr Bull. 2015;41(2):419–428.
   PubMed Web of Science ®Google Scholar
• Lanté F, Meunier J, Guiramand J, et al. Late N‐acetylcysteine treatment prevents the deficits induced in the offspring of dams exposed to an immune stress during gestation. Hippocampus. 2008;18(6):602–609.
   PubMed Web of Science ®Google Scholar
• Matsuura A, Ishima T, Fujita Y, et al. Dietary glucoraphanin prevents the onset of psychosis in the adult offspring after maternal immune activation. Sci Rep. 2018;8(1):1–12.
   PubMedGoogle Scholar
• Amminger GP, McGorry PD. Update on omega-3 polyunsaturated fatty acids in early-stage psychotic disorders. Neuropsychopharmacology. 2012;37(1):309.
   PubMed Web of Science ®Google Scholar
• McGorry PD, Killackey E, Yung A. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry. 2008;7(3):148–156.
   PubMed Web of Science ®Google Scholar
• Sommer IE, van Westrhenen R, Begemann MJ, et al. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull. 2014;40(1):181–191.
   PubMed Web of Science ®Google Scholar
• Dempster K, Jeon P, MacKinley M, et al. Early treatment response in first episode psychosis: a 7-T magnetic resonance spectroscopic study of glutathione and glutamate. Mol Psychiatry. 2020;25(8):1640-1650.
   PubMed Web of Science ®Google Scholar
• Tsugawa S, Noda Y, Tarumi R, et al. Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis. J Psychopharmacol. 2019;33(10):1199–1214.
   PubMed Web of Science ®Google Scholar
• Corcoran C, Gallitano A, Leitman D, et al. The neurobiology of the stress cascade and its potential relevance for schizophrenia. J Psychiatric Pract. 2001;7(1):3–14.
   PubMedGoogle Scholar
• Thompson JL, Pogue-Geile MF, Grace AA. Developmental pathology, dopamine, and stress: a model for the age of onset of schizophrenia symptoms. Schizophr Bull. 2004;30(4):875–900.
   PubMed Web of Science ®Google Scholar
• Nuechterlein KH, Dawson ME. A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr Bull. 1984;10(2):300.
   PubMed Web of Science ®Google Scholar
• van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature. 2010;468(7321):203.
   PubMed Web of Science ®Google Scholar
• Holtzman C, Trotman H, Goulding S, et al. Stress and neurodevelopmental processes in the emergence of psychosis. Neuroscience. 2013;249:172–191.
   PubMed Web of Science ®Google Scholar
• Corcoran C, Smith C, McLaughlin D, et al. HPA axis function and symptoms in adolescents at clinical high risk for schizophrenia. Schizophr Res. 2012;135(1–3):170–174.
   PubMed Web of Science ®Google Scholar
• Walker EF, Trotman HD, Pearce BD, et al. Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study. Biol Psychiatry. 2013;74(6):410–417.
   PubMed Web of Science ®Google Scholar
• Kline E, Thompson E, Bussell K, et al. Psychosis-like experiences and distress among adolescents using mental health services. Schizophr Res. 2014;152(2–3):498–502.
   PubMed Web of Science ®Google Scholar
• Mizrahi R, Addington J, Rusjan PM, et al. Increased stress-induced dopamine release in psychosis. Biol Psychiatry. 2012;71(6):561–567.
   PubMed Web of Science ®Google Scholar
• Sapolsky RM, Uno H, Rebert CS, et al. Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci. 1990;10(9):2897–2902.
   PubMed Web of Science ®Google Scholar
• Sapolsky RM. A mechanism for glucocorticoid toxicity in the hippocampus: increased neuronal vulnerability to metabolic insults. J Neurosci. 1985;5(5):1228–1232.
   PubMed Web of Science ®Google Scholar
• Walker EF, Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol Rev. 1997;104(4):667.
   PubMed Web of Science ®Google Scholar
• Rosenkranz JA, Grace AA. Cellular mechanisms of infralimbic and prelimbic prefrontal cortical inhibition and dopaminergic modulation of basolateral amygdala neurons in vivo. J Neurosci. 2002;22(1):324–337.
   PubMed Web of Science ®Google Scholar
• Rosenkranz JA, Grace AA. Dopamine attenuates prefrontal cortical suppression of sensory inputs to the basolateral amygdala of rats. J Neurosci. 2001;21(11):4090–4103.
   PubMed Web of Science ®Google Scholar
• Belujon P, Grace AA. Regulation of dopamine system responsivity and its adaptive and pathological response to stress. Proc R Soc B. 2015;282(1805):20142516.
   PubMed Web of Science ®Google Scholar
• Gomes FV, Grace AA. Prefrontal cortex dysfunction increases susceptibility to schizophrenia-like changes induced by adolescent stress exposure. Schizophr Bull. 2017;43(3):592–600.
   PubMed Web of Science ®Google Scholar
• Du Y, Grace AA. Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia. Neuropsychopharmacology. 2013;38(10):1881.
   PubMed Web of Science ®Google Scholar
• Du Y, Grace AA. Amygdala hyperactivity in MAM model of schizophrenia is normalized by peripubertal diazepam administration. Neuropsychopharmacology. 2016;41(10):2455–2462.
   PubMed Web of Science ®Google Scholar
• Zhu X, Grace AA. Prepubertal environmental enrichment prevents dopamine dysregulation and hippocampal hyperactivity in MAM schizophrenia model rats. Biol Psychiatry. 2020. DOI:10.1016/j.biopsych.2020.09.023
   PubMedGoogle Scholar
• Gomes FV, Zhu X, Grace AA. Stress during critical periods of development and risk for schizophrenia. Schizophr Res. 2019;213:107–113.
   PubMed Web of Science ®Google Scholar
• Gomes FV, Rincón-Cortés M, Grace AA. Adolescence as a period of vulnerability and intervention in schizophrenia: insights from the MAM model. Neurosci Biobehav Rev. 2016;70:260–270.
   PubMed Web of Science ®Google Scholar
• Caballero A, Diah KC, Tseng KY. Region‐specific upregulation of parvalbumin‐, but not calretinin‐positive cells in the ventral hippocampus during adolescence. Hippocampus. 2013;23(12):1331–1336.
   PubMed Web of Science ®Google Scholar
• Rector NA, Beck AT. Cognitive behavioral therapy for schizophrenia: an empirical review. J Nerv Ment Dis. 2001;189(5):278–287.
   PubMed Web of Science ®Google Scholar
• Patterson TL, Leeuwenkamp OR. Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophr Res. 2008;100(1–3):108–119.
   PubMed Web of Science ®Google Scholar
• Howes OH, Kaar SJ. Antipsychotic drugs: challenges and future directions. World Psychiatry. 2018;17(2):170.
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69(3):220–229.
   PubMed Web of Science ®Google Scholar
• Woods BT. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am J Psychiatry. 1998;155(12):1661–1670.
   PubMed Web of Science ®Google Scholar
• Zipursky RB, Reilly TJ, Murray RM. The myth of schizophrenia as a progressive brain disease. Schizophr Bull. 2013;39(6):1363–1372.
   PubMed Web of Science ®Google Scholar
• Ho B-C, Andreasen NC, Ziebell S, et al. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry. 2011;68(2):128–137.
   PubMed Web of Science ®Google Scholar
• Konopaske GT, Dorph-Petersen K-A, Sweet RA, et al. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry. 2008;63(8):759–765.
   PubMed Web of Science ®Google Scholar
• Konopaske GT, Dorph-Petersen K-A, Pierri JN, et al. Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology. 2007;32(6):1216.
   PubMed Web of Science ®Google Scholar
• Dorph-Petersen K-A, Pierri JN, Perel JM, et al. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology. 2005;30(9):1649.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Tollefson GD, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005;62(4):361–370.
   PubMed Web of Science ®Google Scholar
• McGorry PD, Nelson B, Amminger GP, et al. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clini Psych. 2009;70:1206–1212.
   Google Scholar
• Burke AR, McCormick CM, Pellis SM, et al. Impact of adolescent social experiences on behavior and neural circuits implicated in mental illnesses. Neurosci Biobehav Rev. 2017;76:280–300.
   PubMed Web of Science ®Google Scholar
• Fawcett JW, Oohashi T, Pizzorusso T. The roles of perineuronal nets and the perinodal extracellular matrix in neuronal function. Nat Rev Neurosci. 2019;20(8):451–465.
   PubMed Web of Science ®Google Scholar
• Murthy S, Kane GA, Katchur NJ, et al. Perineuronal nets, inhibitory interneurons, and anxiety-related ventral hippocampal neuronal oscillations are altered by early life adversity. Biol Psychiatry. 2019;85(12):1011–1020.
   PubMed Web of Science ®Google Scholar
• Cabungcal J-H, Steullet P, Morishita H, et al. Perineuronal nets protect fast-spiking interneurons against oxidative stress. Proc Nat Acad Sci. 2013;110(22):9130–9135.
   PubMed Web of Science ®Google Scholar
• Heckers S, Barch DM, Bustillo J, et al. Structure of the psychotic disorders classification in DSM‐5. Schizophr Res. 2013;150(1):11–14.
   PubMed Web of Science ®Google Scholar
• Gillespie AL, Samanaite R, Mill J, et al. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. BMC Psychiatry. 2017;17(1):12.
   PubMedGoogle Scholar
• Demjaha A, Murray RM, McGuire PK, et al. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012;169(11):1203–1210.
   PubMed Web of Science ®Google Scholar
• Mouchlianitis E, Bloomfield MA, Law V, et al. Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophr Bull. 2015;42(3):744–752.
   PubMed Web of Science ®Google Scholar
• Egerton A, Brugger S, Raffin M, et al. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology. 2012;37(11):2515–2521.
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789–796.
   PubMed Web of Science ®Google Scholar
• Goldstein ME, Anderson VM, Pillai A, et al. Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia. Int J Neuropsychopharmacol. 2015;18:6.
   Web of Science ®Google Scholar
• Grace AA, Gomes FV. The circuitry of dopamine system regulation and its disruption in schizophrenia: insights into treatment and prevention. Schizophr Bull. 2019;45(1):148–157.
   PubMed Web of Science ®Google Scholar
• Lewis DA, Curley AA, Glausier JR, et al. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012;35(1):57–67.
   PubMed Web of Science ®Google Scholar
• Sarpal DK, Argyelan M, Robinson DG, et al. Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment. Am J Psychiatry. 2016;173(1):69–77.
   PubMed Web of Science ®Google Scholar
• Sarpal DK, Lencz T, Malhotra AK. In support of neuroimaging biomarkers of treatment response in first-episode schizophrenia. Am J Psychiatry. 2016;173(7):732–733.
   PubMed Web of Science ®Google Scholar
• Dazzan P, Arango C, Fleischacker W, et al. Magnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: a review of current evidence and directions for future research. Schizophr Bull. 2015;41(3):574–583.
   PubMed Web of Science ®Google Scholar
• Mondelli V, Ciufolini S, Belvederi Murri M, et al. Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophr Bull. 2015;41(5):1162–1170.
   PubMed Web of Science ®Google Scholar
• Millan MJ, Andrieux A, Bartzokis G, et al. Altering the course of schizophrenia: progress and perspectives. Nat Rev Drug Discov. 2016;15(7):485.
   PubMed Web of Science ®Google Scholar
• Haroun N, Dunn L, Haroun A, et al. Risk and protection in prodromal schizophrenia:ethical implications for clinical practice and future research. 2006;32(1):166-78.
   Google Scholar
• Lieberman JA, Small SA, Girgis RR. Early detection and preventive intervention in schizophrenia: from fantasy to reality. Am J Psychiatry. 2019;176(10):794–810.
   PubMed Web of Science ®Google Scholar